John Adlesich or the rise of a healthcare manager professional

John Adlesich or the ascent of a health industry manager professional about healthcare industry trends: Successful supply chains are becoming a key differentiator and vital part of the care delivery process in ways we have never seen before in health care. Getting it right requires strategic systems thinking around all functions in the organization. Among the topics for boards to consider: Increasing storage and self-distribution. What’s old is new again. We see a trend toward more self-distribution models instead of just-in-time delivery from distributors. This allows organizations to buy in bulk, control distribution and minimize their reliance on items at risk of being depleted. Organizations do not have a limitless supply of capital so this is not a one-size-fits-all procurement strategy, but it may make sense for certain items in the supply chain.

John Adlesich about behavior therapy in 2021: All behavioral therapies share the same reward/consequence paradigm for changing behavior and learning new skills, and they may include some overlap in the way that they are implemented. Despite these similarities, however, children may respond more fully to one approach over another for any number of unknown reasons. If your child is not developing as you expect, or if you believe that he or she may benefit from a combined approach, then pursuing additional therapies is an option to consider. Sharing your ideas and working cooperatively with the professionals who provide services for your child is a good way to explore the efficacy and practical application of other treatment approaches.

John Adlesich about healthcare industry trends: Democratic control in the Senate will also impact healthcare. For example, Washington state Senator Patty Murray will chair the Senate Committee on Health, Education, Labor, and Pensions. She has advocated for a more robust federal response on COVID-19. And Senator Ron Wyden, Oregon, leads the Finance Committee and has pushed for drug pricing reform and drug price negotiation. These appointments and nominations point to a strong emphasis on COVID-19 recovery and vaccine distribution and coordination. For example, Fauci remains as the Director of the National Institute of Allergies and Infectious Diseases, and there’s now a COVID-19 data director (Shahpar), indicating this administration will emphasize data and reporting. Also evident in these appointments is a Biden administration focus on health equity and healthcare disparities—particularly with Nunez-Smith as the first Equity Task Force Chair for COVID-19. John Adlesich currently works as administrator at Marquis Companies. His latest healthcare industry experience includes positions as executive director at Powerback Rehabilitation Lafayette (Genesis Healthcare) between Aug 2020 – Jan 2021, administrator at Mesa Vista of Boulder between Mar 2019 – Aug 2020, chief executive officer at Sedgwick County Memorial Hospital between Jul 2018 – Feb 2019, interim chief operating officer at Toiyabe Indian Health Project between Mar 2018 – Jun 2018.

John Adlesich thinks that 2021 is an important year for the health industry. Assuming that we do make these great strides in lessening the societal impact of COVID-19 and move to a new normal, I think we will begin to make some key shifts that will ultimately improve health care’s cost, quality, reliability, and underlying data infrastructure. Repeal and replace or Medicare for All? A public option or an individual mandate? Drug price controls or an international pricing index? For the last 10 years, big moves in health care have largely been frozen as providers, insurance companies, investors, and others waited to see which policies would remain permanent and which would end up on the scrap heap of history. The Democrat’s extremely narrow margins of control of government and need to heal the nation by avoiding extreme polarization means that sweeping changes to the Affordable Care Act (ACA) will be off the table—probably not for 200 years, but certainly for the next two years and more likely four. That said, the Biden administration will take advantage of every administrative tool to further cement current law in place. With a legislative détente in place and more stability on implementation, private sector bets become more certain. There is every reason to assume rapid investment and modernization across the health care sector.